The Austrian experience with trabectedin in non-selected patients with metastatic soft tissue sarcoma (STS)

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 8, 2013, Pages 1337-1342

  Ploner, F ^a,h   Lamm, W ^b,c,h   Schur, S ^b,c,h   Eisterer, W ^d,h   Kuhr T ^e   Lindorfer, A ^f   Tinchon, C ^g   Kostler W J ^b,c,h   Szkandera, J ^a   Brodowicz, T ^b,c,h  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Austrian Breast and Colorectal Cancer Study Group   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e Klinikum Wels Grieskirchen GmbH   (Austria)

^f Department of Surgery   (Austria)

^g Regional Hospital   (Austria)

^h Sarcoma Platform Austria   (Austria)

Author keywords

Metastatic; Soft tissue sarcoma; Trabectedin

Indexed keywords

TRABECTEDIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; AUSTRIAN; CANCER FATIGUE; CANCER PAIN; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ETHNIC GROUP; FEBRILE NEUTROPENIA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERSONAL EXPERIENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; SOFT TISSUE SARCOMA; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; AUSTRIA; DIOXOLES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SARCOMA; SOFT TISSUE NEOPLASMS; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84880888054     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1447-8     Document Type: Article

References (18)

1. Blay JY, Italiano A, Ray-Coquard I, Cesne A, Duffaud F, Rios M, Collard O, Bertucci F, Bompas E, Isambert N, Chaigneau L, Cassier P, Bui B, Decanter G, Derbel O, Coindre JM, Zintl P, Badri N, Penel N (2013) Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program. BMC Cancer 13:64 [Epub ahead of print]
2. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gómez J, Park YC, Le Cesne A (2009) Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 27:4188-4196
3. Demetri GD, Le Cesne A, Chawla SP, Brodowicz T, Maki RG, Bach BA, Smethurst DP, Bray S, Hei YJ, Blay JY (2012) First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study. Eur J Cancer 48:547-563
4. Fletcher CDM, Unni KK, Mertens F (2002) World Health Organization Classification of tumours: pathology and genetics of tumours of soft tissue and bone. IARC Press, Lyon
5. Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, Quigley MT, Merriam P, Canniff J, Goss G, Matulonis U, Maki RG, Lopez T, Puchalski TA, Sancho MA, Gomez J, Guzman C, Jimeno J, Demetri GD (2004) Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 22:1480-1490
6. Garcia-Carbonero R, Supko JG, Maki RG, Manola J, Ryan DP, Harmon D, Puchalski TA, Goss G, Seiden MV, Waxman A, Quigley MT, Lopez T, Sancho MA, Jimeno J, Guzman C, Demetri GD (2005) Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 23:5484-5492
7. Le Cesne A, Antoine E, Spielmann M, Le Chevalier T, Brain E, Toussaint C, Janin N, Kayitalire L, Fontaine F, Genin J et al (1995) High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 13:1600-1608
8. Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, Lorigan P, Rodenhuis S, Ray-Coquard I, Bonvalot S, Collin F, Jimeno J, Di Paola E, Van Glabbeke M, Nielsen OS (2005) Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 23:576-584. Erratum in: J Clin Oncol 2005 23:5276
9. Nielsen OS, Judson I, van Hoesel Q, le Cesne A, Keizer HJ, Blay JY, van Oosterom A, Radford JA, Svancárová L, Krzemienlecki K, Hermans C, van Glabbeke M, Oosterhuis JW, Verweij J (2000) Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 36:61-67
10. Palumbo R, Palmeri S, Antimi M, Gatti C, Raffo P, Villani G, Toma S (1997) Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. Ann Oncol 8:1159-1162
11. Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, Hays C, Benjamin RS (1997) High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies-dose-response and schedule dependence. J Clin Oncol 15:2378-2384
12. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, Buesa J, Casali P, Spooner D, Rankin E et al (1995) Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13:1537-1545
13. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics 2012. CA Cancer J Clin 62:10-29
14. Skubitz KM, D'Adamo DR (2007) Sarcoma. Mayo Clin Proc 82:1409-1432. Review
15. van der Graaf WTA, Judson I, Verweij J, et al (2012) Results of a randomised phase III trial (EORTC62012) of single agent doxorubicin versus doxorubicin plus ifosfamide as first line chemotherapy for patients with advanced or metastatic soft tissue sarcoma: a survival study by the EORTC Soft Tissue and Bone Sarcoma Group. Paper presented at: 37th European Society for Medical Oncology Congress; Sept 28-Oct 2, 2012, Vienna, Austria. Abstract LBA7
16. Vezeridis MP, Moore R, Karakousis CP (1983) Metastatic patterns in soft-tissue sarcoma. Arch Surg 118:915-918
17. World Health Organization: WHO handbook for reporting results of cancer treatment. World HealthOrganization Offset Publication No. 48. Geneva, Switzerland, World Health Organization, 1979
18. Yovine A, Riofrio M, Blay JY, Brain E, Alexandre J, Kahatt C, Taamma A, Jimeno J, Martin C, Salhi Y, Cvitkovic E, Misset JL (2004) Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 22:890-899